Natera director Jonathan Sheena sells $603,710 in company stock

On October 16, 2026, Jonathan Sheena, a director and co-founder of Natera, Inc. (NASDAQ: NTRA), sold 1,580 shares of the company's common stock, amounting to approximately $603,710. The trades occurred within a range of $398.9536 and $409.3575 per share. Adopting a Rule 10b5-1 trading plan on June 11, 2026, Sheena sold the shares indirectly for the benefit of the Caraluna 1 Trust and Caraluna 2 Trust, while disclaiming beneficial ownership.

The sale took place as Natera stock approached its 52-week high of $437.41, having achieved a 117% return over the previous year. Analysts consider the stock overvalued relative to its Fair Value, classifying it among the most overvalued in the market. Natera, currently valued at $58.5 billion, has 13 ProTips available to subscribers.

Post these transactions, Sheena personally owns 221,314 shares and indirectly holds 8,250 shares via each trust. Natera's second-quarter revenue exceeded market expectations, reporting $753 million against an anticipated $661.26 million, driven by business growth, full-year revenue guidance increase, and notable achievements like record test volume, enhanced margins, and regulatory approvals.

Analysts, including RBC Capital and Rothschild Redburn, have raised their price targets and advised a Buy on Natera, citing its dominant position in minimal residual disease (MRD) testing and strong growth prospects.